Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01250548 · ClinicalTrials.gov registry record · Phase 2
The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT)
A Phase 2 study, sponsored by Baylor Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT01250548: Completed Phase 2 study, sponsored by Baylor Research Institute.
NCT01250548 is a Phase 2 study that has completed, run by Baylor Research Institute. The registered enrollment target is 34 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01250548, a Phase 2 study, has completed, sponsored by Baylor Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effects of apremilast with a placebo (an inactive substance that looks like apremilast) on you and other people with rheumatoid arthritis. The investigators will be collecting information in this study to help us determine - * the safety of apremilast in patients with active rheumatoid arthritis * how long it takes for patients with active rheumatoid arthritis to respond to apremilast * how long the effects of apremilast last after the treatment has ended.
Interventions
- OTHER Placebo
- BIOLOGICAL apremilast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2010-05 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
What the finished NCT01250548 record still lists
NCT01250548 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01250548 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01250548 about?
NCT01250548 is a clinical study titled "The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT)". The purpose of this study is to compare the effects of apremilast with a placebo (an inactive substance that looks like apremilast) on you and other people with rheumatoid arthritis. The investigators will be collecting information in this study to help us determine - * the safety of apremilast in...
What is the current status of trial NCT01250548?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2010-05. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01250548?
The interventions under investigation include: Placebo (OTHER), apremilast (BIOLOGICAL).
Who is sponsoring clinical trial NCT01250548?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01250548's enrollment target sits among peer trials
34 1539th of 2000 higher than 448 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia